TB-500 10MG

Description

TB-500 10mg research peptide — Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

The 10mg vial is the larger of our two single-compound TB-500 listings. Under that trade name sits either thymosin β4 — the 43-residue, N-acetylated peptide sequenced from calf thymus in 1981 and later shown to be the cell’s main reservoir of monomeric actin^{[1, 2]} — or its acetylated 17–23 fragment, which is what analytical chemists have found in commercial TB-500 preparations^[5]. Which one a given batch contains is a question for that batch’s report. Lyophilized powder, one sealed vial, laboratory research only.

Full research overview, study table & references → TB-500 in Canada: research guide

Identity at a glance

Batch documentation: a batch-specific COA for this strength has not been posted yet — see the COA library. The report for the 5 mg vial (#219841) covers that strength only and is not reproduced here.

What researchers have looked at

• Actin biology: thymosin β4 is the most abundant β-thymosin in mammalian tissue and the main G-actin-sequestering peptide; a 2005 review framed its repair effects in skin, cornea and injured organs around that role^[2].
• Mouse heart (2004): after coronary-artery ligation, thymosin β4 raised integrin-linked kinase and Akt activity, improved early cardiomyocyte survival and improved cardiac function; in culture it formed a complex with PINCH and ILK^[4].
• Mouse epicardium (2007): the peptide was required for coronary vessel development and made quiescent adult epicardial explants produce fibroblasts, smooth-muscle and endothelial cells^[3].
• Horses and doping control (2012): the acetylated LKKTETQ fragment and its metabolites were confirmed in equine plasma and urine after administration of a TB-500 product — a detection method, not an efficacy study^[5].
• Limits: human work is confined to small investigational trials of thymosin β4; a phase I study of recombinant thymosin β4 in 84 healthy volunteers reported mild-to-moderate adverse events and no dose-limiting toxicity^[6]. Nothing here supports any use of TB-500 in people.

Storage and handling

• Frozen at −20 °C for long-term storage of the sealed lyophilized vial (the site gives up to 24 months); short-term in a cool, dry, dark place; no repeated freeze–thaw.
• Soluble in water and saline. Solutions are less stable than powder; bacteriostatic water is stocked separately. Protocols belong to the researcher and are not published here.

Also listed: TB-500 5MG (with a posted Janoshik report) · BPC-157/TB-500 20MG. Canada Post from inside Canada; the shipping policy lists cut-off times and the free-shipping threshold, and the whole range is on our buy peptides online in Canada page.

Frequently asked questions

Is there a certificate of analysis for TB-500 10mg?

Not yet. No batch-specific report for the 10 mg vial is in the COA library at the time of writing. The 5 mg vial’s Janoshik report (#219841) applies to that strength only; we do not reuse it here. The page will be updated when a 10 mg report is posted.

Which molecule does “TB-500” refer to on this listing?

Until a batch report identifies it, we can only say what the trade name covers: full-length thymosin β4 (43 amino acids, about 4963 g/mol) or the acetylated fragment Ac-LKKTETQ (7 amino acids, 889 g/mol) found in TB-500 products by doping-control chemists (PMID 23084823). The mass-spectrometry line on a report is what settles it.

What has thymosin β4 been studied for in animals?

Mostly repair biology in mice and rats: it is the main G-actin-sequestering peptide in cells (PMID 16099219); in mice it activated integrin-linked kinase and Akt after coronary ligation (PMID 15565145) and mobilised adult epicardial progenitor cells (PMID 17108969). These are preclinical findings, not claims about people.

Is TB-500 10mg for human use?

No. Neither thymosin β4 nor its fragment has an approved product in Canada, the US or the EU; the only human data are small investigational trials of thymosin β4 in specific conditions, including a phase I safety study (PMID 34346165). This vial is supplied for laboratory research only, with no dosing or administration guidance.

Cited

1. Low et al. (1981), Proceedings of the National Academy of Sciences of the United States of America — PMID 6940133
2. Goldstein et al. (2005), Trends in molecular medicine — PMID 16099219
3. Smart et al. (2007), Nature — PMID 17108969
4. Bock-Marquette et al. (2004), Nature — PMID 15565145
5. Ho et al. (2012), Journal of chromatography. A — PMID 23084823
6. Wang et al. (2021), Journal of cellular and molecular medicine — PMID 34346165

For laboratory research use only. Not for human or animal consumption. No dosing, administration or protocol information is provided, and nothing here is a claim of efficacy or safety in humans.